Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dranitsaris

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Current Oncology (Toronto, Ont.)|October 27, 2010
Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and LabradorG Dranitsaris, S Edwards, J Edwards, et al.
Gynecologic Oncology|September 23, 1997
Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancerA Ortega, G Dranitsaris, J Sturgeon, et al.
Current Oncology (Toronto, Ont.)|July 14, 2012
Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?M C Gainford, G Dranitsaris, W Ooi, et al.
The Canadian Journal of Hospital Pharmacy|July 9, 1987
Cost effective evaluation of a stability studyS E Walker, Y Hanabusa, G Dranitsaris, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|December 21, 2014
Management of patients with Cushing's disease: a Canadian cost of illness analysisS Van Uum, M Hurry, R Petrella, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Based Paclitaxel in Metastatic Breast Cancer (Mbc): A Cost Utility Analysis from a Chinese Health Care PerspectiveG Dranitsaris, B Yu, Z Qing, et al.
Current Oncology (Toronto, Ont.)|February 28, 2013
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centreS Dent, J Fraser, N Graham, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 13, 2014
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology settingG Dranitsaris, N Beegle, T Kalberer, et al.
Journal of Clinical Pathology|April 29, 2009
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancerE Amir, M Trinkaus, C E Simmons, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 15, 1989
Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteersS E Walker, T W Paton, D H Cowan, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|October 27, 2010
Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and LabradorG Dranitsaris, S Edwards, J Edwards, et al.
Gynecologic Oncology|September 23, 1997
Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancerA Ortega, G Dranitsaris, J Sturgeon, et al.
Current Oncology (Toronto, Ont.)|July 14, 2012
Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?M C Gainford, G Dranitsaris, W Ooi, et al.
The Canadian Journal of Hospital Pharmacy|July 9, 1987
Cost effective evaluation of a stability studyS E Walker, Y Hanabusa, G Dranitsaris, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|December 21, 2014
Management of patients with Cushing's disease: a Canadian cost of illness analysisS Van Uum, M Hurry, R Petrella, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Based Paclitaxel in Metastatic Breast Cancer (Mbc): A Cost Utility Analysis from a Chinese Health Care PerspectiveG Dranitsaris, B Yu, Z Qing, et al.
Current Oncology (Toronto, Ont.)|February 28, 2013
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centreS Dent, J Fraser, N Graham, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 13, 2014
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology settingG Dranitsaris, N Beegle, T Kalberer, et al.
Journal of Clinical Pathology|April 29, 2009
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancerE Amir, M Trinkaus, C E Simmons, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 15, 1989
Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteersS E Walker, T W Paton, D H Cowan, et al.
Pageof 5